DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Malignant Melanoma | Emerging Therapies | Keytruda (pembrolizumab) | US | Wave 1 | 2014
LaunchTrends: Keytruda (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched malignant…
Biomarker-Driven Prescribing in Oncology: Stakeholder Dynamics in Brazil for Breast Cancer, NSCLC, CRC, and Malignant Melanoma | Physician & Payer Forum | Brazil and Mexico | 2014
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Brazil is highly dependent on incorporation into…
Biomarker-Driven Prescribing in Oncology: Stakeholder Dynamics in Mexico and Argentina for Breast Cancer, NSCLC, CRC and Malignant Melanoma | Physician & Payer Forum | Mexico and Argentina | 2014
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Mexico and Argentina is highly dependent on their…
Biomarker-Driven Prescribing in Oncology: Physician and Payer Insights on Evolving Trends in Key Indications | Physician & Payer Forum | US | 2014
Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as varied as…
Getting to Market Quicker: U.S. Physician and Payer Perceptions of Breakthrough Designation for Malignant Melanoma, Breast Cancer, NSCLC, Chronic Lymphocytic Leukemia, and Multiple Myeloma | Physician & Payer Forum | US | 2014
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28…
